INDBInternet News Database 2.5 Updated just now · 377 sources Show or hide images Light or dark

Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's

Save Like Comments Compare coverage
Image from Medpagetoday

Summary

(MedPage Today) -- Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. At 2 years, diranersen continued...

Description from Medpagetoday.

Who is covering this

  1. Medpagetoday Center Factuality: Mostly factual US
    Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's

    (MedPage Today) -- Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. At 2 years, diranersen continued...

Comments

Comments need JavaScript.